Drugs / ZL-1503
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07658482 | Sep 2026 → Feb 2027 expected | — | Zai Lab (Shanghai) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07235384 | Dec 2025 → Dec 2027 expected | atopic eczema | Zai Lab (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-18 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases zailaboratory.com ↗
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from a preclinical study of ZL-1503, demonstrating that the company’s internally developed IL-13/IL-31Rα bispecific antibody may lead to sustained suppression of intense pruritus (itch) and inflammation caused by atopic diseases. |
| 2025-06-13 | Zai Lab (Shanghai) Co., Ltd. | Results Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 zailaboratory.com ↗
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s promising IL-13/IL-31R bispecific antibody, demonstrating its ability to simultaneously suppress the inflammatory and pruritogenic (itch-causing) pathways in atopic dermatitis (AD). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-18 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases zailaboratory.com ↗ |
| 2025-12-08 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis zailaboratory.com ↗ |
| 2025-06-13 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025 zailaboratory.com ↗ |
| 2024-09-17 | Zai Lab (Shanghai) Co., Ltd. | Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024 zailaboratory.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZL-1503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235384 ↗ |
| Route | Intravenous | “single intravenous dose of ZL-1503” NCT07658482 ↗ |